| Species |
Human |
| Protein Construction |
ULBP-2 (Gly26-Ser217)_x000D_
Accession # Q9BZM5 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized ULBP-2, His & Avi, Human at 5μg/ml (100μl/Well) on the plate can bind Human NKG2D, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
24.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway, mediating natural killer cell cytotoxicity. |
| Synonyms |
ALCAN-alpha; N2DL2; NKG2DL2; RAET1H; RAET1L; ULBP2; ULBP-2/5/6; NKG2D ligand 2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
